Skip to main content

Review Experiences and Regulatory Challenges for Pharmaceutical Development in Japan Using a Quality-by-Design Approach

Therapeutic Innovation & Regulatory Science volume 50, pages 368–374 (2016)Cite this article

Abstract

Background

A significant number of inquiries are issued during the review of pharmaceutical products developed using the quality-by-design (QbD) approach in Japan. The purpose of this article was to identify key elements specific to QbD development that should be described in the Quality Overall Summary (QOS) dossier.

Methods

The review reports of the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) were investigated to identify review points for QbD products. Based on the results, key considerations for preparing the QOS of QbD products were determined.

Results

The primary review points for QbD products were control strategy (∼30%), design space (∼15%), and real-time release (∼15%). Additionally, the market authorization application form (AF) was discussed more frequently for QbD products than for products developed using a traditional approach. Based on the results, a “QOS checklist for QbD products” was developed to highlight key elements of QbD products that should be included in the QOS.

Conclusions

It is important to explain the scientific rationale for the control strategy, design space, and real-time release in the QOS and how “regulatory flexibility” is expressed in the AF. The QOS checklist enables applicants to prepare an appropriately detailed QOS that should satisfy the PMDA’s critical review points. The following are recommended for further discussion topics to enable efficient and consistent review by the PMDA for QbD products: (1) Clear guidance on how to express “regulatory flexibility” in the AF and (2) a “QOS checklist for QbD products” that is agreed upon by both regulatory agencies and pharmaceutical companies.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Kagayama K, Ono S. Clinical development and review period of new drugs in Japan—2014 performance [in Japanese]. http://www.jpma.or.jp/opir/news/news-45.pdf. Office Pharm Ind Res News. 2014;45:16–22.

    Google Scholar 

  2. US Food and Drug Administration. Final report on pharmaceutical cGMPs for the 21st century—a risk-based approach. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/QuestionsandAnswersonCurrentGoodManufacturingPracticescGMPforDrugs/ucm137175.htm. Updated December 17, 2014.

  3. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline, pharmaceutical development Q8 (R2). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf. Published August 2009.

  4. Lawrence XY. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008;25:781–791.

    Article  Google Scholar 

  5. Kourti T, Davis B. The business benefits of quality by design (QbD). Pharm Eng. 2012;32:1–10.

    Google Scholar 

  6. ICH Quality Implementation Working Group. Points to consider (R2), ICH-endorsed guide for ICH Q8/Q9/Q10 implementation. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_9_10_QAs/PtC/Quality_IWG_PtCR2_6dec2011.pdf. Published December 6, 2011.

  7. Hiyama Y. Research on the rapid and efficient process construction of pharmaceutical manufacturing or development and approval review—research on establishment of design space for critical processes and real time release as a control strategy, etc. [in Japanese]. Health and Labor Sciences Research Grants in FY 2008, Joint Research Report. http://www.nihs.go.jp/drug/section3/H20Okuda1GRep.pdf.

  8. Okuda H. Research on development and manufacturing information of drug substances —R&D of drug substances by the methodology of quality by design [in Japanese]. Health and Labor Sciences Research Grants in FY 2008, Joint Research Report. http://www.nihs.go.jp/drug/section3/H23OkudaRRep.pdf.

  9. Katori N. Research on quality assurance for pharmaceutical drugs—research on quality assurance for drug product through lifecycle [in Japanese]. Health and Labor Sciences Research Grants in FY 2008, Joint Research Report. http://www.nihs.go.jp/drug/section3/H25_OkudaSeizai_houkoku.pdf.

  10. Mastuda Y. PMDA perspective on regulatory commitments, Paper presented at: 2014 American Association of Pharmaceutical Science (AAPS) Annual Meeting and Exposition; November 2–6, 2014; San Diego. http://www.pmda.go.jp/files/000153420.pdf.

  11. Ministry of Health, Labor and Welfare. PFSB/ELD Notification No. 0210001: Guideline for descriptions on application forms for marketing approval of drugs, etc. under the revised pharmaceutical affairs law, https://www.pmda.go.jp/files/000153677.pdf. Published February 10, 2005.

  12. Pharmaceuticals and Medical Devices Agency. The pharmaceutical and medical devices agency annual report FY2013. https://www.pmda.go.jp/files/000203634.pdf.

  13. US Food and Drug Administration. Question-based review for CMC evaluations of ANDAs, http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm120971.htm#. Updated December 6, 2014.

  14. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline, good manufacturing practice guide for active pharmaceutical ingredients Q7. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Step4/Q7_Guideline.pdf. Published November 10, 2000.

  15. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline, development and manufacture of drug substances (chemical entities and biotechnological / biological entities) Q11. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q11/Q11_Step_4.pdf. Published May 1, 2012.

Download references

Author information

Affiliations

  1. KITANOMARU SQUARE, MSD K.K., 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, 102-8667, Japan

    Kiyohito Kuno MS

  2. Laboratory of Regulatory Science, Faculty of Pharmacy, Musashino University, Tokyo, Japan

    Kiyohito Kuno MS & Satoshi Toyoshima PhD

Authors
  1. Kiyohito Kuno MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoshi Toyoshima PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kiyohito Kuno MS.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kuno, K., Toyoshima, S. Review Experiences and Regulatory Challenges for Pharmaceutical Development in Japan Using a Quality-by-Design Approach. Ther Innov Regul Sci 50, 368–374 (2016). https://doi.org/10.1177/2168479015620832

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479015620832

Keywords

  • quality-by-design (QbD)
  • control strategy
  • design space
  • real-time release (RTR)
  • quality overall summary